Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYSA1901 vs Pertuzumab in Neoadjuvant HER2+ Breast Cancer
NCT05720026Phase 3Recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jan 2023
- Primary completion
- Aug 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pertuzumab in HER2-positive breast cancer (2 arms), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoint: Total Pathologic Complete Response up to 5 months. Started Jan 2023; status: recruiting.
02
Drugs
pertuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05720026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720026.